IP Library Granted Patent US 8,877,209
Granted Patent B2
US 8,877,209 · App. 13/113,244 · Granted Nov 4, 2014

Recombinant influenza vectors with tandem transcription units

Inventors: Yoshihiro Kawaoka (Middleton, WI); Gabriele Neumann (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12N15/86A61K2039/5254A61K48/0091A61K2039/525A61K39/145C12N2760/16234C12N2760/16161C12N2760/16151C12N2760/16251A61K2039/5256C12N2760/16134C12N2760/16143A61K2039/5252C12N2760/16051C12N7/00C12N2760/16243C12N2760/16043C12N2760/16261
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,209
App. No.
13/113,244
Granted
Nov 4, 2014
Kind
B2
Abstract

The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.

Claims (10)

1. A set of three plasmids for influenza virus production together having eight transcription cassettes for influenza virus vRNA production and four transcription cassettes for influenza virus mRNA production, wherein the transcription cassettes for vRNA production include a transcription cassette comprising a PolI promoter operably linked to an influenza virus PA cDNA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus PB1 cDNA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus PB2 cDNA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus HA cDNA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus NP cDNA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus NA cDNA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus M cDNA linked to a PolI transcription termination sequence, and a transcription cassette comprising a PolI promoter operably linked to an influenza virus NS cDNA linked to a PolI transcription termination sequence; wherein the transcription cassettes for mRNA production include a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PA linked to a PolII transcription termination sequence, a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PB1 linked to a PolII transcription termination sequence, a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PB2 linked to a PolII transcription termination sequence, and a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus NP linked to a PolII transcription termination sequence, and wherein transfection of a cell with the three plasmids yields titers of at least 1×10 2 TCID 50 /mL.

2. The set of claim 1 , wherein one plasmid has eight transcription cassettes for vRNA production.

3. The set of claim 2 , wherein one plasmid has one transcription cassette for mRNA production and another plasmid has three transcription cassettes for mRNA production.

4. The set of claim 1 , wherein one plasmid has six transcription cassettes for vRNA production and another plasmid has two transcription cassettes for vRNA production.

5. The set of claim 4 , wherein one plasmid has four transcription cassettes for mRNA production.

6. The set of claim 1 , wherein the HA is a type A HA.

7. The set of claim 1 , wherein the HA is a type B HA.

8. A method to prepare influenza virus, comprising: contacting a cell with the set of plasmids of claim 1 , or in an amount effective to yield infectious influenza virus.

9. A composition comprising the set of plasmids of claim 1 .

10. The set of claim 5 , wherein the two transcription cassettes for vRNA production are for HA and NA.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2014
From: KAWAOKA, YOSHIHIRO; NEUMANN, GABRIELE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 034233/0814 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2014
From: KAWAOKA, YOSHIHIRO; NEUMANN, GABRIELE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 034178/0367 →
CONFIRMATORY LICENSE Recorded May 26, 2011
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026347/0160 →
Continuity (3)
Continuation 11283498 · Nov 18, 2005
Provisional Application 60629665 · Nov 19, 2004
Related Publication 20110300604A1 · Dec 8, 2011